This topic contains a solution. Click here to go to the answer

Author Question: Technetium-99m, xenon-133, and gallium-67 are radiopharmaceutical drugs that ________. A) emit ... (Read 31 times)

s.tung

  • Hero Member
  • *****
  • Posts: 577
Technetium-99m, xenon-133, and gallium-67 are radiopharmaceutical drugs that ________.
 
  A) emit positrons
  B) are combined with monoclonal antibodies
  C) contain iodine
  D) emit gamma rays

Question 2

The superior end of the spinal cord attaches to the cerebellum of the brain.
 
  Indicate whether the statement is true or false



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

dajones82

  • Sr. Member
  • ****
  • Posts: 359
Answer to Question 1

D
Explanation: A) These drugs do not emit positrons.
B) These drugs are not combined with monoclonal antibodies.
C) These drugs do not contain iodine.
D) Correct

Answer to Question 2

FALSE
Explanation: The superior end of the spinal cord attaches to, and is continuous with, the medulla oblongata of the brainstem.




s.tung

  • Member
  • Posts: 577
Reply 2 on: Jun 27, 2018
Great answer, keep it coming :)


alexanderhamilton

  • Member
  • Posts: 334
Reply 3 on: Yesterday
YES! Correct, THANKS for helping me on my review

 

Did you know?

For pediatric patients, intravenous fluids are the most commonly cited products involved in medication errors that are reported to the USP.

Did you know?

If all the neurons in the human body were lined up, they would stretch more than 600 miles.

Did you know?

A seasonal flu vaccine is the best way to reduce the chances you will get seasonal influenza and spread it to others.

Did you know?

Looking at the sun may not only cause headache and distort your vision temporarily, but it can also cause permanent eye damage. Any exposure to sunlight adds to the cumulative effects of ultraviolet (UV) radiation on your eyes. UV exposure has been linked to eye disorders such as macular degeneration, solar retinitis, and corneal dystrophies.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library